AnPac Bio (NASDAQ: ANPC), a biotechnology company with operations in the United States and China focused on early cancer screening and detection and a business-to-business (“B2B”) food e-commerce company, announced that in December 2022 and January 2023, the company signed definitive agreements with several third party investors. According to the update, the investors agreed to purchase 29,714,279 newly issued Class A ordinary shares (1,485,714 American Depositary Shares or “ADSs”) of the company at a price of $0.175 per ordinary share or $3.50 per ADS (1:20 ADS-to-share ratio), for a total purchase price of $5.2 million. The closing is expected to take place within 30 days of signing, after which AnPac Bio expects to use the proceeds for its B2B Asian food e-commerce and Asian food supply chain construction.
To view the full press release, visit https://ibn.fm/For4J
About AnPac Bio-Medical Science Co. Ltd.
AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 155 issued patents as of June 30, 2022. With two certified clinical laboratories in China and one CLIA and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including CDA (Cancer Differentiation Analysis), bio-chemical, immunological, and genomics tests. The company also has a B2B food e-commerce business. For more information, visit www.AnPacBio.com.
NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.investorwire.com
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
InvestorWire is part of the InvestorBrandNetwork.